We investigated the relevance of the three-TF signature to regulation mechanisms of glioma carcinogenesis and suggested AHR, NFIL3 and ZNF423 as promising biomarkers for not only glioma molecular subtype diagnosis but also clinical treatment. This evidence concerns the gene TF and glioma.